Article
Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
The Journal of pathology - 1 Nov 2015
Saunus Jodi M, Quinn Michael C J, Patch Ann-Marie, Pearson John V, Bailey Peter J, Nones Katia, McCart Reed Amy E, Miller David, Wilson Peter J, Al-Ejeh Fares, Mariasegaram Mythily, Lau Queenie, Withers Teresa, Jeffree Rosalind L, Reid Lynne E, Da Silva Leonard, Matsika Admire, Niland Colleen M, Cummings Margaret C, Bruxner Timothy J C, Christ Angelika N, Harliwong Ivon, Idrisoglu Senel, Manning Suzanne, Nourse Craig, Nourbakhsh Ehsan, Wani Shivangi, Anderson Matthew J, Fink J Lynn, Holmes Oliver, Kazakoff Stephen, Leonard Conrad, Newell Felicity, Taylor Darrin, Waddell Nick, Wood Scott, Xu Qinying, Kassahn Karin S, Narayanan Vairavan, Taib Nur Aishah, Teo Soo-Hwang, Chow Yock Ping, kConFab, Jat Parmjit S, Brandner Sebastian, Flanagan Adrienne M, Khanna Kum Kum, Chenevix-Trench Georgia, Grimmond Sean M, Simpson Peter T, Waddell Nicola, Lakhani Sunil R
Abstract excerpt
Treatment options for patients with brain metastases (BMs) have limited efficacy and the mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our understanding of mechanisms underpinning metastatic outgrowth in the brain is limited. To address these deficiencies, we investigated the genomic and transcriptomic landscapes of 36 BMs from breast, lung, melanoma and oesophageal cancers,...
Read the complete abstract on PubMed